The new geography of pharma manufacturing in the Americas

 

Pharmaceutical manufacturing strategy across the Americas is entering a new phase shaped by resilience planning and geopolitical uncertainty. For much of the past two decades, pharmaceutical supply chains were built around global optimisation, with companies prioritising scale and cost advantages across dispersed manufacturing networks. Today, that model is being reassessed.

Companies are increasingly adopting a regional network approach, balancing domestic capacity with strategic partnerships and targeted investment across the Americas. Manufacturing decisions are now shaped as much by risk exposure and supply continuity as by labour costs or operational efficiency.

This evolution reflects a wider change in how governments and industry view pharmaceutical supply chains. Medicines are increasingly treated as strategic assets, with manufacturing infrastructure linked to national and economic security and public health preparedness. As a result, the Americas are emerging as a more interconnected manufacturing ecosystem in which the United States, Latin America and regional contract development and manufacturing organisation (CDMO) networks each play distinct but complementary roles.

From global optimisation to regional resilience

The COVID-19 pandemic exposed the fragility of highly concentrated global supply chains, particularly for critical active pharmaceutical ingredients (APIs) and biologics. Since then, supply disruption has remained a persistent concern, driven by public health events as well as geopolitical instability, trade tensions and regulatory pressure.

This has accelerated interest in nearshoring and regionalisation across the pharmaceutical manufacturing industry. However, the reality is more complex than a straightforward reshoring trend. Few companies are abandoning global manufacturing entirely. Instead, many are redesigning supply chains to reduce dependence on a single geography while creating greater flexibility across multiple sites and partners.

In the Americas, this often means combining US-based manufacturing with expanded partnerships in Mexico, Brazil, Canada and other emerging production hubs. Companies are seeking manufacturing footprints that can reduce transportation exposure and provide alternative production routes when disruptions occur.

The conversation has also expanded beyond APIs and generics into biologics, advanced therapies and fill-finish operations, where regional manufacturing capability is becoming strategically important. Governments across the region are simultaneously examining how domestic production incentives, procurement frameworks and policies can strengthen pharmaceutical self-sufficiency without isolating markets from global trade.

How manufacturing strategy becomes a risk strategy

Trade policy and geopolitics are now playing a larger role in manufacturing decisions. Tariff uncertainty and broader geopolitical tensions are influencing where companies choose to manufacture, source materials and establish partnerships. Key factors shaping manufacturing strategy include:

• Tariff exposure and trade restrictions affecting cross-border operations
• Concerns about overreliance on single-country sourcing models
• Pressure to build redundancy into supply chains through regional partnerships
• The need for manufacturing networks that can respond quickly to disruption
• Greater focus on supply continuity alongside cost and efficiency

As a result, manufacturing location is increasingly viewed as a risk-management decision rather than purely a cost-management exercise. Companies are assessing whether manufacturing networks can withstand regulatory disruption, shipping delays, political instability or sudden changes in trade policy.

CDMOs reshape the manufacturing map

CDMOs are playing a central role in this transition. While greenfield expansion remains important, many CDMOs are accelerating growth through facility acquisitions rather than entirely new construction.

Recent industry activity suggests that acquiring existing pharmaceutical manufacturing sites has become an increasingly attractive route to expanding regional capacity. For CDMOs, acquisitions provide faster access to infrastructure, skilled labour, regulatory approvals and established production capabilities. For pharmaceutical companies, divesting facilities can offer greater operational flexibility while maintaining manufacturing access through partnerships.

This trend is reshaping the manufacturing landscape in the Americas. Rather than building entirely new manufacturing corridors, companies are repurposing and integrating existing assets into broader regional production networks.

Emerging hubs and cross-border partnerships

The new geography of pharma manufacturing in the Americas is not centred on one country alone. While the US remains the region’s largest pharmaceutical market and a major centre for advanced manufacturing investment, other countries are strengthening their roles within regional supply chains. Several markets are emerging with distinct strategic advantages:

• Mexico
  Proximity to the US market, industrial manufacturing base and trade integration
• Brazil
  Strong domestic pharmaceutical demand and expanding biologics capability
• Canada
  Growing investment in biopharmaceutical manufacturing and R&D infrastructure
• Regional CDMO networks
  Increasing capacity through acquisitions, partnerships and multi-site operations

This is creating a more interconnected manufacturing model in which countries contribute different capabilities and supply-chain advantages. Cross-border partnerships are becoming increasingly important because no single market can independently provide the full range of manufacturing resilience required across the pharmaceutical sector.

A long-term structural shift

The current transformation of the geography of pharmaceutical manufacturing in the Americas is unlikely to be temporary. Many of the pressures driving change (such as geopolitical fragmentation, resilience planning, industrial policy and supply security concerns) are structural rather than cyclical.

At the same time, companies still face the economic realities of pharmaceutical manufacturing, including pricing pressure and regulatory complexity. The challenge is to create manufacturing networks that remain commercially viable while also being more resilient. This tension is likely to define the next phase of pharmaceutical manufacturing strategy. The future may belong to hybrid regional ecosystems capable of balancing efficiency with resilience, rather than fully localised or globalised supply chains.

Across the Americas, that shift is already underway. Manufacturing geography is increasingly being determined by cost and scale and by how effectively companies can build flexible, interconnected and politically resilient production networks in an increasingly uncertain world.